Forest Labs gets Lexapro protection
How does Forest Labs spell relief? P-A-T-E-N-T. A federal court has validated the company's Lexapro protection, safeguarding that blockbuster antidepressant and antianxiety drug through 2012. The court also intervened to stop Teva Pharmaceuticals from launching a generic version of Lexapro, which is Forest's top seller at $2 billion per year.
- check out the release
Related Articles:
FDA OKs generic Lexapro. Report
Lundbeck chair hits exit. Report
Forest Labs dumps failed stroke drug program. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets